And with the help of deep learning techniques, it provides diagnostic quality imaging.

Blue Earth will be sharing anonymized clinical data from its Phase 3 Lighthouse trial involving the use of PET imaging agent Posluma.

A team of experts determined that correlating masses initially detected on MRI are significantly more likely to result in a cancer diagnosis than other common findings. 

The agent was found to be better than standard CT imaging for patients with clear cell renal cell cancer.

The model incorporates specific data from MRI exams with patient risk factors to predict whether a person is likely to develop clinically significant prostate cancer.

This development could help scientists fine-tune speech therapy to people who struggle with speaking. 

This week at the International Society for Magnetic Resonance in Medicine’s annual meeting, a team of experts presented new data on the technologist’s role in MRI safety events.

Machine learning models could help create a more standardized, reproducible and efficient way of grading Crohn’s disease severity in the small bowel based on CT imaging.